Cargando…
A Phase I Trial of Pox PSA vaccines (PROSTVAC(®)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
PURPOSE: Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (desi...
Autores principales: | DiPaola, RS, Plante, M, Kaufman, H, Petrylak, DP, Israeli, R, Lattime, E, Manson, K, Schuetz, T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360095/ https://www.ncbi.nlm.nih.gov/pubmed/16390546 http://dx.doi.org/10.1186/1479-5876-4-1 |
Ejemplares similares
-
Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy
por: Lucas, Julie L., et al.
Publicado: (2017) -
Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014) -
ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway
Publicado: (1993) -
Phase I Neoadjuvant Study of Intravesical Recombinant Fowlpox-GM-CSF (rF-GMCSF) or Fowlpox-TRICOM (rF-TRICOM) in Patients with Bladder Carcinoma
por: Portal, Daniella E., et al.
Publicado: (2019) -
Role of LFA-1 and ICAM-1 in Cancer
por: Reina, Manuel, et al.
Publicado: (2017)